Treatment of autoimmune myasthenia gravis

Neurology

Volumn 61, Issue 12, 2003, Pages 1652-1661

  Richman, David P ^a   Agius, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EPHEDRINE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; NICOTINIC RECEPTOR; PREDNISONE; PROTEIN TYROSINE KINASE; PYRIDOSTIGMINE;

ABDOMINAL CRAMP; ALGORITHM; ANXIETY DISORDER; AVASCULAR NECROSIS; BLADDER DISEASE; BONE MARROW SUPPRESSION; BRADYCARDIA; CATARACT; CLINICAL FEATURE; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; COST BENEFIT ANALYSIS; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG CHOICE; FASCICULATION; GLAUCOMA; HUMAN; HYPERTENSION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSOMNIA; LEUKOPENIA; LIVER DYSFUNCTION; MYASTHENIA GRAVIS; MYOPATHY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PSYCHOSIS; RESPIRATORY TRACT DISEASE; REVIEW; THROMBOCYTOPENIA; THYMECTOMY; VOMITING; WEIGHT GAIN;

EID: 0347994922     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000098887.24618.A0     Document Type: Review

References (75)

1. Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci USA 1980;77:755-759.
2. Richman DP, Patrick J, Arnason BG. Cellular immunity in myasthenia gravis. Response to purified acetylcholine receptor and autologous thymocytes. N Engl J Med 1976;294:694-698.
3. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977;52:267-280.
4. Gomez CM, Richman DP. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci USA 1983;80:4089-4093.
5. Lefvert AK, Cuenoud S, Fulpius BW. Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis. J Neuroimmunol 1981;1:125-135.
6. Richman DP, Agius MA, Kirvan CA, et al. Antibody effector mechanisms in myasthenia gravis. The complement hypothesis. Ann NY Acad Sci 1998;841:450-465.
7. Maselli RA, Richman DP, Wollmann RL. Inflammation at the neuromuscular junction in myasthenia gravis. Neurology 1991;41:1497-1504.
8. Nakano S, Engel AG. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 1993;43:1167-1172.
9. Wolf SM, Rowland LP, Schotland DL, McKinney AS, Hoefer PF, Aranow H Jr. Myasthenia as an autoimmune disease: clinical aspects. Ann NY Acad Sci 1966;135:517-535.
10. Mossman S, Vincent A, Newsom-Davis J. Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect. J Neurol Sci 1988;84:15-28.
11. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
12. Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 2002;25:4-16.
13. Burke G, Cossins J, Maxwell S, et al. Rapsyn mutations in hereditary myasthenia: distinct early and late phenotypes. Neurology 2003;61:826-828.
14. Strauss AJ, Seegal BC, Hsu KC, Burkholder PM, Nastuk WL, Osserman KE. Immunofluorescence demonstration of a muscle-binding complement-fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol Med 1960;105:184-191.
15. Aarli JA, Stefansson K, Marton LS, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990;82:284-288.
16. Voltz RD, Albrich WC, Nagele A, et al. Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology 1997;49:1454-1457.
17. Mygland A, Aarli JA, Matre R, Gilhus NE. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57:843-846.
18. Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 2000;57:1596-1600.
19. Agius MA, Zhu S, Kirvan CA, et al. Rapsyn antibodies in myasthenia gravis. Ann NY Acad Sci 1998;841:516-521.
20. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2:85-95.
21. Agius MA, Twaddle GM, Fairclough RH. Epitope spreading in experimental autoimmune myasthenia gravis. Ann NY Acad Sci 1998;841:365-367.
22. Bird HA. Current management of rheumatoid arthritis. Br J Hosp Med 1986;35:374-381.
23. Khamashta MA, Ruiz-Irastorza G, Hughes GR. Systemic lupus erythematosus flares during pregnancy. Rheum Dis Clin North Am 1997;23:15-30.
24. Verhasselt V, Goldman M. From autoimmune responses to autoimmune disease: what is needed? J Autoimmun 2001;16:327-330.
25. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998;280:243-248.
26. Campbell H, Bramwell E. Myasthenia gravis. Brain 1900;23:277-337.
27. Kennedy FS, Moersch FP. Myasthenia gravis: a clinical review of eighty-seven cases observed between 1915 and the early part of 1932. CMAJ 1937;37:216-223.
28. Viets HR. A historical review of myasthenia gravis from 1672 to 1900. JAMA 1953;153:1273-1280.
29. Rowland LP, Hoefer PFA, Aranow H, Merritt HH. Fatalities in myasthenia gravis: a review of 39 cases with 26 autopsies. Neurology 1956;6:307-326.
30. Verma P, Oger J. Treatment of acquired autoimmune myasthenia gravis: a topic review. Can J Neurol Sci 1992;19:360-375.
31. Perlo VP, Poskanzer DC, Schwab RS, Viets HR, Osserman KE, Genkins G. Myasthenia gravis: evaluation of treatment in 1,355 patients. Neurology 1966;16:431-439.
32. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-318.
33. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706.
34. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etan-ercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593.
35. Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-356.
36. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-285.
37. Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann NY Acad Sci 1981;377:652-669.
38. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-2311.
39. Sanders DB, El Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-1980.
40. Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 1934;1:1200-1201.
41. Sieb JP, Engel AG. Ephedrine: effects on neuromuscular transmission. Brain Res 1993;623:167-171.
42. Lundh H, Nilsson O, Rosen I. Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine. Eur Arch Psychiatry Neurol Sci 1985;234:374-377.
43. Barrons RW. Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy 1997;17:1220-1232.
44. Buckingham JM, Howard FM Jr, Bernatz PE, et al. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg 1976;184:453-458.
45. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:7-15.
46. Romi F, Gilhus NE, Varhaug JE, Myking A, Skeie GO, Aarli JA. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur J Neurol 2002;9:55-61.
47. DeFilippi VJ, Richman DP, Ferguson MK. Transcervical thymectomy for myasthenia gravis. Ann Thorac Surg 1994;57:194-197.
48. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am J Ther 2001;8:123-143.
49. Barnes PJ. Molecular mechanisms of corticosteroids in allergic diseases. Allergy 2001;56:928-936.
50. Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 1974;290:81-84.
51. Warmolts JR, Engel WK. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med 1972;286:17-20.
52. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-299.
53. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50:1778-1783.
54. Elion GB. Significance of azathioprine metabolites. Proc R Soc Med 1972;65:257-260.
55. Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci 1997;150:59-62.
56. Kuks JB, Djojoatmodjo S, Oosterhuis HJ. Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature. Neuromuscul Disord 1991;1:423-431.
57. Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Ann Neurol 1984;15:602-605.
58. Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology 1986;36:35-39.
59. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293-2301.
60. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 2002;3:89-98.
61. Zhu LP, Cupps TR, Whalen G, Fauci AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 1987;79:1082-1090.
62. Perez MC, Buot WL, Mercado-Danguilan C, Bagabaldo ZG, Renales LD. Stable remissions in myasthenia gravis. Neurology 1981;31:32-37.
63. Niakan E, Harati Y, Rolak LA. Immunosuppressive drug therapy in myasthenia gravis. Arch Neurol 1986;43:155-156.
64. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993;681:539-551.
65. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000;47:119-125.
66. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
67. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-96.
68. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97-99.
69. Pinching AJ, Peters DK. Remission of myasthenia gravis following plasma-exchange. Lancet 1976;2:1373-1376.
70. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977;297:1134-1140.
71. Pinching AJ, Peters DK, Davis JN. Plasma exchange in myasthenia gravis. Lancet 1977;1:428-429.
72. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apheresis Sci 2003;28:249-255.
73. Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986;146:1365-1368.
74. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study. Ann Neurol 1997;41:789-796.
75. Ronager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001;25:967-973.